| ［1］ |
Engel M， Hoffmann T， Wagner L，et al. The crystal structure of dipeptidyl peptidase Ⅳ （CD26） reveals its functional regulation and enzymatic mechanism［J］. Proc Natl Acad Sci USA， 2003， 100（9）： 5063-5068. DOI： 10.1073/pnas.0230620100.
|
| ［2］ |
Röhrborn D， Eckel J， Sell H. Shedding of dipeptidyl peptidase 4 is mediated by metalloproteases and up‐regulated by hypoxia in human adipocytes and smooth muscle cells［J］. FEBS Lett， 2014， 588（21）： 3870-3877. DOI： 10.1016/j.febslet.2014.08.029.
|
| ［3］ |
Herrera C， Morimoto C， Blanco J，et al. Comodulation of CXCR4 and CD26 in human lymphocytes［J］ . J Biol Chem， 2001， 276（22）： 19532-19539. DOI： 10.1074/jbc.M004586200.
|
| ［4］ |
Ikushima H， Munakata Y， Ishii T，et al. Internalization of CD26 by mannose 6-phosphate/insulin-like growth factor Ⅱ receptor contributes to T cell activation［J］. Proc Natl Acad Sci USA， 2000， 97（15）： 8439-8444. DOI： 10.1073/pnas.97.15.8439.
|
| ［5］ |
Baticic Pucar L， Pernjak Pugel E， Detel D，et al. Involvement of DPP Ⅳ/CD26 in cutaneous wound healing process in mice［J］. Wound Repair Regen， 2017， 25（1）： 25-40. DOI： 10.1111/wrr.12498.
|
| ［6］ |
Aertgeerts K， Ye S， Shi L，et al. N-linked glycosylation of dipeptidyl peptidase Ⅳ （CD26）： effects on enzyme activity，homodimer formation，and adenosine deaminase binding［J］. Protein Sci， 2004， 13（1）： 145-154. DOI： 10.1110/ps.03352504.
|
| ［7］ |
Zhang G， Liu B， Qiao D，et al. PROTAC-mediated structure–function disruption of CD26： a therapeutic strategy for driver-negative non-small cell lung cancer［J］. eBioMedicine， 2025， 122： 106026. DOI： 10.1016/j.ebiom.2025.106026.
|
| ［8］ |
Ohnuma K， Uchiyama M， Yamochi T，et al. Caveolin-1 triggers T-cell activation via CD26 in association with CARMA1［J］. J Biol Chem， 2007， 282（13）： 10117-10131. DOI： 10.1074/jbc.M609157200.
|
| ［9］ |
Ohnuma K， Yamochi T， Uchiyama M，et al. CD26 up-regulates expression of CD86 on antigen-presenting cells by means of caveolin-1［J］. Proc Natl Acad Sci USA， 2004， 101（39）： 14186-14191. DOI： 10.1073/pnas.0405266101.
|
| ［10］ |
Kawakita E， Koya D， Kanasaki K. CD26/DPP-4： type 2 diabetes drug target with potential influence on cancer biology［J］. Cancers， 2021， 13（9）： 2191. DOI： 10.3390/cancers13092191.
|
| ［11］ |
Rinkevich Y， Walmsley GG， Hu MS，et al. Identification and isolation of a dermal lineage with intrinsic fibrogenic potential［J］. Science， 2015， 348（6232）： aaa2151. DOI： 10.1126/science.aaa2151.
|
| ［12］ |
Mascharak S， desJardins-Park HE， Davitt MF，et al. Preventing Engrailed-1 activation in fibroblasts yields wound regeneration without scarring［J］. Science， 2021， 372（6540）： eaba2374. DOI： 10.1126/science.aba2374.
|
| ［13］ |
Wu M， Matar DY， Yu Z，et al. Continuous NPWT regulates fibrosis in murine diabetic wound healing［J］. Pharmaceutics， 2022， 14（10）： 2125. DOI： 10.3390/pharmaceutics14102125.
|
| ［14］ |
Mascharak S， des Jardins-Park HE， Davitt MF，et al. Modulating cellular responses to mechanical forces to promote wound regeneration［J］. Adv Wound Care， 2022， 11（9）： 479-495. DOI： 10.1089/wound.2021.0040.
|
| ［15］ |
|
| ［16］ |
Worthen CA， Cui Y， Orringer JS，et al. CD26 identifies a subpopulation of fibroblasts that produce the majority of collagen during wound healing in human skin［J］. J Invest Dermatol， 2020， 140（12）： 2515-2524. e3. DOI： 10.1016/j.jid.2020.04.010.
|
| ［17］ |
Michalak-Micka K， Klar AS， Dasargyri A，et al. The influence of CD26 + and CD26 - fibroblasts on the regeneration of human dermo-epidermal skin substitutes［J］. Sci Rep， 2022， 12（1）： 1944. DOI： 10.1038/s41598-022-05309-5.
|
| ［18］ |
Vorstandlechner V， Laggner M， Copic D，et al. The serine proteases dipeptidyl-peptidase 4 and urokinase are key molecules in human and mouse scar formation［J］. Nat Commun， 2021， 12（1）： 6242. DOI： 10.1038/s41467-021-26495-2.
|
| ［19］ |
Liang N， Zhang C， Dill P，et al. Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex［J］. J Exp Med， 2014， 211（11）： 2249-2263. DOI： 10.1084/jem.20140341.
|
| ［20］ |
Patel PM， Jones VA， Kridin K，et al. The role of dipeptidyl peptidase-4 in cutaneous disease［J］. Exp Dermatol， 2021， 30（3）： 304-318. DOI： 10.1111/exd.14228.
|
| ［21］ |
Lee SY， Wu ST， Liang YJ，et al. Soluble dipeptidyl peptidase-4 induces fibroblast activation through proteinase-activated receptor-2［J］. Front Pharmacol， 2020， 11：552818. DOI： 10.3389/fphar.2020.552818.
|
| ［22］ |
Zhang J， Zhou J， Tang C，et al. Sustained-release sitagliptin microneedles for scar prevention via fibroblast-to-adipocyte conversion［J］. Small Sci， 2025， 5（12）： e202500140. DOI： 10.1002/smsc.202500140.
|
| ［23］ |
Love KM， Liu Z. DPP4 activity，hyperinsulinemia，and atherosclerosis［J］. J Clin Endocrinol Metab， 2021， 106（6）： 1553-1565. DOI： 10.1210/clinem/dgab078.
|
| ［24］ |
Jiang Y， Yao Y， Li J，et al. Functional dissection of CD26 and its pharmacological inhibition by sitagliptin during skin wound healing［J］. Med Sci Monit， 2021， 27：e928933. DOI： 10.12659/MSM.928933.
|
| ［25］ |
Dai X， Zeng J， Yan X，et al. Sitagliptin-mediated preservation of endothelial progenitor cell function via augmenting autophagy enhances ischaemic angiogenesis in diabetes［J］. J Cell Mol Med， 2018， 22（1）：89-100. DOI： 10.1111/jcmm.13296.
|
| ［26］ |
Schürmann C， Linke A， Engelmann-Pilger K，et al. The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice［J］. J Pharmacol Exp Ther， 2012， 342（1）： 71-80. DOI： 10.1124/jpet.111.191098.
|
| ［27］ |
Li X， Zhang KW， Zhang ZY，et al. Inhibiting dipeptidyl peptidase 4 positive fibroblasts using zinc sulfide cellulose nanofiber scaffolds to achieve scarless healing［J］. Int J Biol Macromol， 2024， 282： 137525. DOI： 10.1016/j.ijbiomac.2024.137525.
|
| ［28］ |
Gao W， Chen D， He H，et al. Sitagliptin，a DPP-4 inhibitor，effectively promotes the healing of diabetic foot ulcer： a randomized controlled trial［J］. J Diabetes， 2025， 17（9）： e70156. DOI： 10.1111/1753-0407.70156.
|
| ［29］ |
Lee CH， Huang CH， Hung KC，et al. Nanofibrous vildagliptin/PLGA membranes accelerate diabetic wound healing by angiogenesis［J］. Pharmaceuticals （Basel）， 2022， 15（11）：1358. DOI： 10.3390/ph15111358.
|
| ［30］ |
Shao S， Zhang N， Specht GP，et al. Pharmacological expansion of type 2 alveolar epithelial cells promotes regenerative lower airway repair［J］. Proc Natl Acad Sci USA， 2024， 121（16）： e2400077121. DOI： 10.1073/pnas.2400077121.
|
| ［31］ |
Koyanagi Y， Kawasaki T， Kasuya Y，et al. Functional roles of CD26/DPP4 in bleomycin-induced pulmonary fibrosis［J］. Physiol Rep， 2023， 11（6）：e15645. DOI： 10.14814/phy2.15645.
|
| ［32］ |
Liu Y， Qi Y. Vildagliptin，a CD26/DPP4 inhibitor，ameliorates bleomycin-induced pulmonary fibrosis via regulating the extracellular matrix［J］ . Int Immunopharmacol， 2020， 87： 106774. DOI： 10.1016/j.intimp.2020.106774.
|
| ［33］ |
Suzuki T， Tada Y， Gladson S，et al. Vildagliptin ameliorates pulmonary fibrosis in lipopolysaccharide-induced lung injury by inhibiting endothelial-to-mesenchymal transition［J］. Respir Res， 2017， 18（1）： 177. DOI： 10.1186/s12931-017-0660-4.
|
| ［34］ |
Duarte N， Coelho I， Holovanchuk D，et al. Dipeptidyl peptidase-4 is a pro-recovery mediator during acute hepatotoxic damage and mirrors severe shifts in kupffer cells［J］. Hepatol Commun， 2018， 2（9）： 1080-1094. DOI： 10.1002/hep4.1225.
|
| ［35］ |
Zhang H， Sun D， Wang G，et al. Alogliptin alleviates liver fibrosis via suppression of activated hepatic stellate cell［J］. Biochem Biophys Res Commun， 2019， 511（2）： 387-393. DOI： 10.1016/j.bbrc.2019.02.065.
|
| ［36］ |
Kaji K， Yoshiji H， Ikenaka Y，et al. Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats［J］. J Gastroenterol， 2014， 49（3）： 481-491. DOI： 10.1007/s00535-013-0783-4.
|
| ［37］ |
Li J， Xu Y， Wang M，et al. Dual-source DPP4 drives intestinal fibrosis in Crohn's disease： synergistic therapeutic targeting of host and microbiota pathways［J］. Gut Microbes， 2025， 17（1）： 2593119. DOI： 10.1080/19490976.2025.2593119.
|
| ［38］ |
Chen S， Lin Y， Yang H，et al. A CD26 + tendon stem progenitor cell population contributes to tendon repair and heterotopic ossification［J］. Nat Commun， 2025， 16（1）： 749. DOI： 10.1038/s41467-025-56112-5.
|
| ［39］ |
廖萌. 西格列汀对糖尿病大鼠的骨保护作用及其与TLR4/NF-κB表达关系的研究［D］. 福州：福建医科大学，2014.
|
| ［40］ |
Aeimlapa R， Panmanee J， Teerapornpuntakit J，et al. Vildagliptin and omarigliptin differentially bind to DPP-4 homodimers and modulate osteoclast-mediated bone resorption［J］. Compr Physiol， 2026， 16（1）： e70103. DOI： 10.1002/cph4.70103.
|
| ［41］ |
Carmichael E， Reme AIS， Bosco PJ，et al. Biological regulation of HIF-1α and its role in therapeutic angiogenesis for treatment of ischemic cardiovascular disease［J］. Int J Mol Sci， 2025， 26（22）： 11236. DOI： 10.3390/ijms262211236.
|
| ［42］ |
Sharifi MA， Yasin NF， Kamarul T，et al. The regenerative journey： exploring stem cell roles from injury detection to tissue repair［J］. Stem Cell Res Ther， 2025， 16： 1-15. DOI： 10.1186/s13287-025-04609-7.
|
| ［43］ |
Janssens R， Mortier A， Boff D，et al. Truncation of CXCL12 by CD26 reduces its CXC chemokine receptor 4- and atypical chemokine receptor 3-dependent activity on endothelial cells and lymphocytes［J］. Biochem Pharmacol， 2017， 132： 92-101. DOI： 10.1016/j.bcp.2017.03.009.
|
| ［44］ |
Tomović Pavlović K， Anderluh M， Šmelcerović A. Mechanisms of beneficial effects of DPP-4 inhibitors as a promising perspective for the prevention/treatment of the disruption of cardio-cerebrovascular homeostasis［J］. Front Pharmacol， 2025， 16： 1642333. DOI： 10.3389/fphar.2025.1642333.
|
| ［45］ |
Ding L， Zhang J. Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells［J］. Acta Pharmacol Sin， 2012， 33（1）： 75-81. DOI： 10.1038/aps.2011.149.
|
| ［46］ |
Huang C， Shih C， Tsao N，et al. Dipeptidyl peptidase‐4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cells［J］. Br J Pharmacol， 2012， 167（7）： 1506-1519. DOI： 10.1111/j.1476-5381.2012.02102.x.
|
| ［47］ |
Chua S， Lee FY， Tsai TH，et al. Inhibition of dipeptidyl peptidase-Ⅳ enzyme activity protects against myocardial ischemia-reperfusion injury in rats［J］. J Transl Med， 2014， 12（1）： 357. DOI： 10.1186/s12967-014-0357-0.
|
| ［48］ |
Choi SH， Park S， Oh CJ，et al. Dipeptidyl peptidase-4 inhibition by gemigliptin prevents abnormal vascular remodeling via NF-E2-related factor 2 activation［J］. Vascul Pharmacol， 2015， 73： 11-19. DOI： 10.1016/j.vph.2015.07.005.
|
| ［49］ |
Jiang T， Jiang D， Zhang L，et al. Anagliptin ameliorates high glucose- induced endothelial dysfunction via suppression of NLRP3 inflammasome activation mediated by SIRT1［J］. Mol Immunol， 2019， 107：54-60. DOI： 10.1016/j.molimm.2019.01.006.
|
| ［50］ |
You S， Bi Y， Miao M，et al. Plasma sDPP4 （soluble dipeptidyl peptidase-4） and cognitive impairment after noncardioembolic acute ischemic stroke［J］. Stroke， 2023， 54（1）： 113-121. DOI： 10.1161/STROKEAHA.122.040798.
|
| ［51］ |
Oh Y， Cho Y. Dipeptidyl peptidase 4 as an injury-responsive protein in the mouse sciatic nerve［J］. Mol Cells， 2024， 47（12）： 100159. DOI： 10.1016/j.mocell.2024.100159.
|